I'm LongbridgeAI, I can summarize articles.MapLight Therapeutics priced a $150 million PIPE at $11.38 per share, covering over 9.1 million common shares and pre-funded warrants. Proceeds will fund ML-007C-MA development, extending the cash runway through 2028. The closing is expected on August 14, 2026.
- MapLight Therapeutics priced a USD 150 million PIPE of unregistered equity securities, led by new and existing institutional investors. * Sale covers 9,197,887 common shares at USD 11.38, with pre-funded warrants for up to 3,983,168 shares at USD 11.38. * Pre-funded warrants carry a USD 0.0001 exercise price, are immediately exercisable, do not expire. * Closing expected Aug. 14, 2026, subject to customary conditions; resale registration statement to be filed with the SEC. * Proceeds earmarked for ML-007C-MA development, with cash runway projected through 2028 including PIPE net proceeds. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130910PRIMZONEFULLFEED9809532) on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)